Soozan Omran¹, Reihane Kazerani¹ and Mohammad Hossein Modarressi²*

¹Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
²Department of Medical Genetics, School of Medicine, Tehran University of Medical Science, Tehran, Iran

*Corresponding Author: Mohammad Hossein Modarressi, Department of Medical Genetics, School of Medicine, Tehran University of Medical Science, Tehran, Iran.

Received: March 30, 2025; Published: April 10, 2025

Abstract

Introduction: Prostate cancer, with a high rate among men, is the second cause of death among men. DNA methylation patterns and chromatin structure change in cancer. Thus, the present study investigates the methylation status of the MCPH1 gene in samples of malignant prostate cancer tumor tissue in comparison with the surrounding normal tissue and benign prostatic hyperplasia (BPH).

Material and Methods: In this study, 104 samples (47 samples of malignant tumor tissue, 47 samples of normal surrounding tissue, and 10 samples of BPH) were collected. After DNA extraction, all samples were treated with bisulfite. The methylation status of genes was examined through the MS-HRM technique and by designing specific primers for this method on treated DNA samples. Finally, the collected data were analyzed using SPSS software.

Results: The results revealed that regarding the MCPH1 gene, methylated samples in the malignant tumor group are higher than normal and BPH. There is a significant relationship between the disease status and the methylation level of the samples, so the level of methylation in normal tissue and BPH tissue is lower than that in malignant tumor tissue (p-value<0.001). No significant differ ence was observed between the methylation status of the samples and their age (P-value: 0.9). Also, in people whose both lobes were involved in the malignant tumor, the samples were in the methylated status regarding the MCPH1 gene. Also, a significant relationship was observed between the involvement of both lobes and MCPH1 gene methylation.

Conclusion: Based on the observations of the present study, it can be stated that the methylation changes are proportional to the Gleason score, but this relationship was not significant. MCPH1 gene methylation changes seem to play a significant role in the patho genesis of prostate cancer and can be used as a diagnostic marker in prostate cancer.

Keywords: Prostate Cancer; MCPH1 Gene Methylation; BPH Samples; Gleason Score

References

1. Hamilton W., et al. “Clinical features of prostate cancer before diagnosis: a population-based, case-control study”. British Journal of General Practice 531 (2006): 756-762.
2. Jackson AP., et al. “Primary autosomal recessive microcephaly (MCPH1) maps to chromosome 8p22-pter”. American Journal of Human Genetics 2 (1998): 541-546.
3. P JA. “Identification of microcephalin, a protein implicated in determining the size of the human brain”. American Journal of Human Genetics1 (2012): 136-142.
4. “MCPH1 ENSG00000147316”. (2017a).
5. Venkatesh T., et al. “Primary microcephaly gene MCPH1 shows signatures of tumor suppressors and is regulated by miR-27a in oral squamous cell carcinoma”. PLoS One3 (2013): e54643.
6. Tervasmäki A., et al. “Tumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly”. International Journal of Cancer8 (2019): 2070-2081.
7. Kopparapu PK., et al. “MCPH1 maintains long-term epigenetic silencing of ANGPT2 in chronic lymphocytic leukemia”. Febs Journal10 (2015): 1939-1952.
8. Jones PA and Baylin SB. “The fundamental role of epigenetic events in cancer”. Nature Reviews Genetics6 (2002): 415-428.
9. Baylin SB and Jones PA. “Epigenetic Determinants of Cancer”. Cold Spring Harbor Perspectives 9 (2016).
10. Bhattacharya N., et al. “Frequent alterations of MCPH1 and ATM are associated with primary breast carcinoma: clinical and prognostic implications”. Annals of Surgical Oncology 20 (2013): S424-432.
11. Ghodsi M., et al. “Investigation of promoter methylation of MCPH1 gene in circulating cell-free DNA of brain tumor patients”. Experimental Brain Research9 (2020): 1903-1909.
12. Karami F., et al. “Key Role of Promoter Methylation and Inactivation of MCPH1 Gene in Brain Tumors”. Journal of Neurology Research5-6 (2015).
13. Liang Y., et al. “Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model”. Oncogene33 (2015): 4368-4378.
14. Wojdacz TK., et al. “Methylation-sensitive high-resolution melting”. Nature Protocols12 (2008): 1903-1908.
15. Wojdacz TK., et al. “Primer design versus PCR bias in methylation independent PCR amplifications”. Epigenetics4 (2009): 231-234.
16. Moses-Fynn E., et al. “Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men”. PLoS One9 (2018): e0203322.
17. Delgado-Cruzata ., et al. “DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer”. DNA Cell Biology2 (2012): 187-192.
18. Richardson J., et al. “Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation”. Breast Cancer Research and Treatment3 (2011): 639-648.
19. Mai L., et al. “The overexpression of MCPH1 inhibits cell growth through regulating cell cycle-related proteins and activating cytochrome c-caspase 3 signaling in cervical cancer”. Molecular and Cellular Biochemistry 1 (2014): 95-107.
20. Tzelepi V., et al. “Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression”. Pathology 2 (2020): 218-227.

Citation

Citation: Mohammad Hossein Modarressi., et al. “Investigating MCPH1 Gene Methylation in Prostate Cancer Tissue".Acta Scientific Paediatrics 8.5 (2025): 14-22.

Copyright

Copyright: © 2025 Mohammad Hossein Modarressi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.